Oncolytic Virotherapy Market Size to Reach USD 342.64 Million by 2035, Driven by Immuno-Oncology Research and Combination Therapies

According to DataM Intelligence, the global oncolytic virotherapy market size reached USD 32.91 million in 2025 and is projected to reach USD 342.64 million by 2035, growing at a 26.4% CAGR during 2026-2035. The market covers approved oncolytic-virus products and the broader development landscape involving engineered viral platforms, clinical programs, manufacturing activities and combination-treatment strategies.
The market is being shaped by growing research into viruses that selectively infect and destroy cancer cells while stimulating antitumor immune responses. Development is increasingly focused on genetically engineered herpes simplex viruses, adenoviruses, vaccinia viruses and other platforms, particularly those designed to express therapeutic payloads or work alongside checkpoint inhibitors, chemotherapy and radiotherapy. Intratumoral delivery remains important, while systemic and other administration approaches are being investigated to expand treatment to inaccessible and metastatic tumors.

Get More Insights from the Full Research Report:
https://www.datamintelligence.com/research-report/oncolytic-virotherapy-market?indhu

Recent Developments

• June 2026, Vyriad announced new clinical development activity for its oncolytic virus therapy portfolio. The company is advancing engineered viral therapies designed to selectively target cancer cells while stimulating anti-tumor immune responses, supporting continued momentum in the U.S. oncolytic virotherapy pipeline.
• April 2026, Genelux Corporation, Candel Therapeutics, CG Oncology and other biotechnology companies remained active in advancing oncolytic virus candidates across multiple cancer indications. The expanding clinical pipeline is increasingly focused on improving tumor targeting, immune activation and combination-treatment strategies.
• January 2026, Novotech highlighted continued growth in global oncolytic virus clinical research, with increasing activity around engineered viral platforms, combination therapies and immune-based approaches. The development reflects growing pharmaceutical and biotechnology interest in using oncolytic viruses as targeted cancer immunotherapies.
• June 2026, Oncolys BioPharma received approval from Japan's Ministry of Health, Labour and Welfare for Telomelysin (suratadenoturev) for the treatment of esophageal cancer. The approval represents a significant development for Japan's oncolytic virotherapy sector and expands clinical use of an oncolytic adenovirus therapy.

Mergers & Acquisitions

• Gilead Sciences & Interius BioTherapeutics - February 2026: Gilead Sciences agreed to acquire Interius BioTherapeutics for up to US$350 million, strengthening its cell-therapy platform and expanding its capabilities in genetic medicine, which are strategically relevant to the development of next-generation cancer immunotherapies alongside oncolytic virus approaches.
• GSK & Nuvalent - June 2026: GSK agreed to acquire Nuvalent for US$10.6 billion, significantly expanding its oncology portfolio with late-stage targeted therapies for non-small-cell lung cancer and reinforcing pharmaceutical investment in innovative cancer-treatment platforms.
• Eli Lilly & Vaccine Company - May 2026: Eli Lilly agreed to acquire Vaccine Company for up to US$1.55 billion, adding an Epstein-Barr virus vaccine program to its pipeline and strengthening its broader virus-focused biotechnology capabilities.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for Quick Response): https://www.datamintelligence.com/download-sample/oncolytic-virotherapy-market?indhu

Oncolytic Virotherapy Market Segmentation

By Virus Platform
• Herpes Simplex Virus
• Adenovirus
• Vaccinia Virus
• Reovirus
• Coxsackievirus
• Poliovirus
• Vesicular Stomatitis Virus
• Newcastle Disease Virus
• Measles Virus
• Other Platforms
Virus platforms form the biological foundation of oncolytic virotherapy and are selected based on their tumor-targeting ability, replication characteristics, safety profile, and potential to stimulate antitumor immune responses. Different viral platforms are being investigated across a broad range of cancer indications.

By Engineering Strategy
• Naturally Occurring
• Attenuated
• Tumor-Selective
• Retargeted
• Cytokine-Armed
• Checkpoint-Expressing
• Bispecific-Expressing
• Multi-Payload Viruses
Engineering strategies are designed to improve tumor selectivity, therapeutic activity, safety, and immune stimulation. Advances in viral engineering are enabling the development of modified platforms capable of selectively targeting cancer cells and delivering immune-modulating or other therapeutic payloads.

By Route of Administration
• Intratumoral
• Intravenous
• Intravesical
• Intracavitary
• Intra-Arterial
• Other Routes
Route of administration influences viral delivery, tumor accessibility, treatment distribution, and therapeutic effectiveness. Intratumoral and systemic approaches are being explored alongside specialized delivery methods to address localized and disseminated tumors.

By Indication
• Melanoma
• Bladder Cancer
• Glioblastoma
• Head and Neck Cancer
• Lung Cancer
• Pancreatic Cancer
• Colorectal Cancer
• Ovarian Cancer
• Breast Cancer
• Prostate Cancer
• Sarcoma
• Other Cancers
Oncolytic virotherapy is being investigated across multiple cancer types because of its potential to selectively target malignant cells while stimulating antitumor immunity. Research and clinical development span solid tumors including melanoma, bladder cancer, glioblastoma, lung cancer, pancreatic cancer, colorectal cancer, and other malignancies.

By Treatment Strategy
• Monotherapy
• Combination Therapy
Treatment strategies include the use of oncolytic viruses alone or alongside other therapeutic approaches. Combination therapy is being explored to enhance antitumor responses by integrating viral activity with immunotherapies, chemotherapy, targeted therapies, or other cancer treatments.

By End User
• Academic Cancer Centers
• Oncology Hospitals
• Clinical-Trial Centers
• Interventional Radiology Centers
• Specialist Clinics
End users support the development, administration, evaluation, and monitoring of oncolytic virotherapy. Academic cancer centers and clinical-trial centers contribute to research and clinical development, while oncology hospitals, interventional radiology centers, and specialist clinics support treatment delivery and patient management.

By Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa
Regional adoption is influenced by cancer research activity, clinical-trial development, healthcare infrastructure, regulatory progress, and investment in advanced oncology therapies. Increasing research into viral immunotherapies and growing clinical development activities are supporting opportunities across major regional markets.

Competitive Landscape

The competitive landscape includes companies with approved oncolytic-virus products, late-stage clinical programs and earlier-stage engineered-virus platforms. Competition is influenced by virus-platform differentiation, clinical efficacy, delivery methods, manufacturing capability, combination potential and regulatory progress.

Top 5 Key Players

• Amgen
• Shanghai Sunway Biotech
• CG Oncology
• Replimune
• Candel Therapeutics

Company Profiles

Amgen: Amgen is associated with IMLYGIC, or talimogene laherparepvec, a genetically modified HSV-1-based oncolytic immunotherapy. Its approved product provides important commercial and clinical precedent for intratumoral oncolytic-virus treatment in melanoma.

Shanghai Sunway Biotech: Shanghai Sunway Biotech is associated with H101, a recombinant adenovirus approved in China for use with chemotherapy in selected head and neck cancer settings. Its product demonstrates the jurisdiction-specific commercial development of adenovirus-based oncolytic therapy.

CG Oncology: CG Oncology is developing oncolytic-virus therapy with a focus on bladder cancer. Its clinical development activities represent the importance of intravesical adenovirus-based approaches within the broader pipeline.
Replimune: Replimune is an oncolytic-virus developer included among the commercially important companies identified in the report. Its presence reflects continued investment in engineered viral platforms and immuno-oncology applications.

Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/oncolytic-virotherapy-market?indhu

Regional Analysis: Europe

Europe represents an important market and development region, although the supplied report identifies North America as the largest market and Asia-Pacific as the fastest-growing region. The report page provided does not disclose a specific percentage market share for Europe, so a percentage is not inserted to avoid introducing an unsupported figure.
The European market is supported by an established biotechnology ecosystem, academic cancer centers and pharmaceutical partnerships. Development activity is influenced by advanced-therapy regulation, clinical research infrastructure and the ability of specialist oncology centers to administer complex treatments.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=oncolytic-virotherapy-market?indhu

Conclusion

The oncolytic-virus field is developing from a small commercial base into a broader oncology platform supported by advances in viral engineering, immuno-oncology research and combination treatment strategies. Approved products such as IMLYGIC and Delytact provide important regulatory and commercial precedents, while a larger pipeline of adenovirus, HSV, vaccinia, reovirus and other platforms continues to expand the development landscape.
Companies with differentiated viral platforms, strong clinical evidence, scalable manufacturing and access to capable treatment centers are likely to be better positioned as the market develops through 2035. The continued expansion of clinical research and investment provides a foundation for further commercialization, although pipeline attrition and regulatory requirements will remain important considerations.

Industry Related Reports

Peptide Drug Conjugate Market Size
The global Peptide Drug Conjugate Market reached an estimated US$ 4.53 billion in 2025 and is expected to reach US$ 25.90 billion by 2035, growing at a CAGR of 19.0% during 2026-2035. Market growth is supported by expanding peptide-based targeted delivery systems, particularly in oncology, along with the development of cytotoxic peptide conjugates, peptide-oligonucleotide conjugates, and multifunctional therapeutic platforms.

Give more insights: https://www.datamintelligence.com/research-report/peptide-drug-conjugate-market?indhu

Nanobody Drug Conjugate Market Share
The global Nanobody Drug Conjugate Market reached an estimated US$ 0.31 billion in 2025 and is expected to reach US$ 2.18 billion by 2035, growing at a CAGR of 21.5% during 2026-2035. Growth is supported by advances in nanobody engineering, targeted drug delivery, modular multispecific designs, and the potential for improved tissue penetration and more controllable therapeutic exposure.

Give more insights: https://www.datamintelligence.com/research-report/nanobody-drug-conjugate-market?indhu

Explore more Japan Reports: https://www.datamintelligence.com/jp-market-research-report?indhu

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.